Role of IL‑13 in Atopic Dermatitis (AD)
0 SAR
الدفع
المقدمة
هذا الفصل لـ
- Physician
- Resident / Fellow
الفئات ذات الصلة
- Deep Response to IL‑13 and IL‑4/13 Inhibition in AD
- Is FACE/Neck AD Treatable? A Real Patient Case with Dr. Fares Alkhayal
- Ebglyss Monthly Maintenance Dosing.Simply No lab monitoring , No boxed warning & No dose adjustment
- Discover the 2 Years effcacy data of Ebglyss in Atopic Dermatitis – ADjoin Trial Highlights
- Ebglyss Clinical Trials: Proven Efficacy in Atopic Dermatitis – Advocate 1 and 2 Insights
- Ebglyss features a unique mechanism of action—binding to interleukin-13 with high affinity and a slow dissociation rate
- Unmet Medical Needs in Atopic Dermatitis: Ebglyss – A New IL-13 inhibitor Biologic for Moderate to Severe AD
- Empowering Atopic Dermatitis Management with Ebglyss Start Strong, Last Long, Maintain Monthly